Purpose This review provides an update on the current clinical, epidemiological and
pathophysiological evidence alongside the diagnostic, prevention and treatment approach …

Cisplatin is one of the most widely used chemotherapeutic agents for various solid tumors in
the clinic due to its high efficacy and broad spectrum. The antineoplastic activity of cisplatin …

Chemotherapy-induced peripheral neuropathy (CIPN) is a major challenge, with increasing
impact as oncological treatments, using potentially neurotoxic chemotherapy, improve …

This review provides an update on the current clinical and preclinical understanding of
chemotherapy induced peripheral neuropathy (CIPN). The overview of the clinical syndrome …

With a 3‐fold increase in the number of cancer survivors noted since the 1970s, there are
now over 28 million cancer survivors worldwide. Accordingly, there is a heightened …

Purpose Given that the clinical course of oxaliplatin-induced neuropathy is not well defined,
the current study was performed to better understand clinical parameters associated with its …

Pain is a common problem in cancer survivors, especially in the first few years after
treatment. In the longer term, approximately 5% to 10% of survivors have chronic severe …

Anti-cancer drugs such as vincristine, paclitaxel, oxaliplatin, cisplatin and bortezomib are
well reported to exert direct and indirect effects on sensory nerves to alter the amplitude of …

With advances in treatment, colorectal cancer (CRC) is being transformed from a deadly
disease into an illness that is increasingly curable. With this transformation has come …

BACKGROUND: The objective of the current prospective, multicenter, international study
was to trace the incidence and severity of acute oxaliplatin‐induced peripheral neuropathy …